Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction

Tsunehiro Takahashi, Yoshiro Saikawa, Takahiro Igarashi, Shinichi Tsuwano, Koshi Kumagai, Rieko Nakamura, Takashi Ooyama, Norihito Wada, Hiroya Takeuchi, Hiromasa Takaishi, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

Advanced gastric cancer frequently RESULTS in the inability to ingest food or drink orally, a condition called malignant gastrointestinal obstruction (MGO). MGO is clinically defned as a gastrointestinal outlet obstruction caused by a large tumor, or malignant bowel obstruction with peritoneal dissemination. MGO impacts the quality of life by interfering with oral intake and by causing gastrointestinal symptoms, such as nausea, vomiting and abdominal pain. Octreotide acetate (OA) is an analogue of somatostatin which has been increasingly used to relieve gastrointestinal symptoms since it decreases the secretion of digestive juices and increases the absorption of water and electrolytes. In Japan, the oral anticancer drug S-1 was recently adopted as a key chemotherapeutic agent in advanced gastric cancer; however, its oral formulation precludes its utility in the MGO setting. This is a pilot study of chemoradiotherapy plus OA in gastric cancer with MGO. Patients were initially treated with OA to control gastrointestinal symptoms. Following resolution of their symptoms, the patients received chemotherapy with S-1 plus low-dose cisplatin and radiation. Irradiation was targeted at the primary tumor and surrounding lesions, including the lymph nodes. Grade 4 toxicity was observed in only 1 patient, and no treatment-related deaths were noted. After treatment, 3 patients achieved a partial response and 4 achieved stable disease. Of the 9 patients, 8 were able to tolerate solid food orally and were discharged. The outcomes of these cases suggest that OA is a useful adjunctive therapy that enables advanced gastric cancer patients with MGO to receive S-1-containing chemotherapy.

Original languageEnglish
Pages (from-to)673-677
Number of pages5
JournalOncology Letters
Volume1
Issue number4
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Octreotide
Chemoradiotherapy
Stomach Neoplasms
Pharmaceutical Preparations
Drug Therapy
Food
Somatostatin
Nausea
Abdominal Pain
Cisplatin
Electrolytes
Vomiting
Neoplasms
Japan
Therapeutics
Lymph Nodes
Quality of Life
Radiation
Water

Keywords

  • Chemoradiotherapy
  • Gastric cancer
  • Malignant gastrointestinal obstruction
  • Octreotide acetate
  • S-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction. / Takahashi, Tsunehiro; Saikawa, Yoshiro; Igarashi, Takahiro; Tsuwano, Shinichi; Kumagai, Koshi; Nakamura, Rieko; Ooyama, Takashi; Wada, Norihito; Takeuchi, Hiroya; Takaishi, Hiromasa; Kitagawa, Yuukou.

In: Oncology Letters, Vol. 1, No. 4, 07.2010, p. 673-677.

Research output: Contribution to journalArticle

Takahashi, Tsunehiro ; Saikawa, Yoshiro ; Igarashi, Takahiro ; Tsuwano, Shinichi ; Kumagai, Koshi ; Nakamura, Rieko ; Ooyama, Takashi ; Wada, Norihito ; Takeuchi, Hiroya ; Takaishi, Hiromasa ; Kitagawa, Yuukou. / Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction. In: Oncology Letters. 2010 ; Vol. 1, No. 4. pp. 673-677.
@article{3f7b3301c6ec4df69153bc58e5962dc2,
title = "Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction",
abstract = "Advanced gastric cancer frequently RESULTS in the inability to ingest food or drink orally, a condition called malignant gastrointestinal obstruction (MGO). MGO is clinically defned as a gastrointestinal outlet obstruction caused by a large tumor, or malignant bowel obstruction with peritoneal dissemination. MGO impacts the quality of life by interfering with oral intake and by causing gastrointestinal symptoms, such as nausea, vomiting and abdominal pain. Octreotide acetate (OA) is an analogue of somatostatin which has been increasingly used to relieve gastrointestinal symptoms since it decreases the secretion of digestive juices and increases the absorption of water and electrolytes. In Japan, the oral anticancer drug S-1 was recently adopted as a key chemotherapeutic agent in advanced gastric cancer; however, its oral formulation precludes its utility in the MGO setting. This is a pilot study of chemoradiotherapy plus OA in gastric cancer with MGO. Patients were initially treated with OA to control gastrointestinal symptoms. Following resolution of their symptoms, the patients received chemotherapy with S-1 plus low-dose cisplatin and radiation. Irradiation was targeted at the primary tumor and surrounding lesions, including the lymph nodes. Grade 4 toxicity was observed in only 1 patient, and no treatment-related deaths were noted. After treatment, 3 patients achieved a partial response and 4 achieved stable disease. Of the 9 patients, 8 were able to tolerate solid food orally and were discharged. The outcomes of these cases suggest that OA is a useful adjunctive therapy that enables advanced gastric cancer patients with MGO to receive S-1-containing chemotherapy.",
keywords = "Chemoradiotherapy, Gastric cancer, Malignant gastrointestinal obstruction, Octreotide acetate, S-1",
author = "Tsunehiro Takahashi and Yoshiro Saikawa and Takahiro Igarashi and Shinichi Tsuwano and Koshi Kumagai and Rieko Nakamura and Takashi Ooyama and Norihito Wada and Hiroya Takeuchi and Hiromasa Takaishi and Yuukou Kitagawa",
year = "2010",
month = "7",
doi = "10.3892/ol_00000118",
language = "English",
volume = "1",
pages = "673--677",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction

AU - Takahashi, Tsunehiro

AU - Saikawa, Yoshiro

AU - Igarashi, Takahiro

AU - Tsuwano, Shinichi

AU - Kumagai, Koshi

AU - Nakamura, Rieko

AU - Ooyama, Takashi

AU - Wada, Norihito

AU - Takeuchi, Hiroya

AU - Takaishi, Hiromasa

AU - Kitagawa, Yuukou

PY - 2010/7

Y1 - 2010/7

N2 - Advanced gastric cancer frequently RESULTS in the inability to ingest food or drink orally, a condition called malignant gastrointestinal obstruction (MGO). MGO is clinically defned as a gastrointestinal outlet obstruction caused by a large tumor, or malignant bowel obstruction with peritoneal dissemination. MGO impacts the quality of life by interfering with oral intake and by causing gastrointestinal symptoms, such as nausea, vomiting and abdominal pain. Octreotide acetate (OA) is an analogue of somatostatin which has been increasingly used to relieve gastrointestinal symptoms since it decreases the secretion of digestive juices and increases the absorption of water and electrolytes. In Japan, the oral anticancer drug S-1 was recently adopted as a key chemotherapeutic agent in advanced gastric cancer; however, its oral formulation precludes its utility in the MGO setting. This is a pilot study of chemoradiotherapy plus OA in gastric cancer with MGO. Patients were initially treated with OA to control gastrointestinal symptoms. Following resolution of their symptoms, the patients received chemotherapy with S-1 plus low-dose cisplatin and radiation. Irradiation was targeted at the primary tumor and surrounding lesions, including the lymph nodes. Grade 4 toxicity was observed in only 1 patient, and no treatment-related deaths were noted. After treatment, 3 patients achieved a partial response and 4 achieved stable disease. Of the 9 patients, 8 were able to tolerate solid food orally and were discharged. The outcomes of these cases suggest that OA is a useful adjunctive therapy that enables advanced gastric cancer patients with MGO to receive S-1-containing chemotherapy.

AB - Advanced gastric cancer frequently RESULTS in the inability to ingest food or drink orally, a condition called malignant gastrointestinal obstruction (MGO). MGO is clinically defned as a gastrointestinal outlet obstruction caused by a large tumor, or malignant bowel obstruction with peritoneal dissemination. MGO impacts the quality of life by interfering with oral intake and by causing gastrointestinal symptoms, such as nausea, vomiting and abdominal pain. Octreotide acetate (OA) is an analogue of somatostatin which has been increasingly used to relieve gastrointestinal symptoms since it decreases the secretion of digestive juices and increases the absorption of water and electrolytes. In Japan, the oral anticancer drug S-1 was recently adopted as a key chemotherapeutic agent in advanced gastric cancer; however, its oral formulation precludes its utility in the MGO setting. This is a pilot study of chemoradiotherapy plus OA in gastric cancer with MGO. Patients were initially treated with OA to control gastrointestinal symptoms. Following resolution of their symptoms, the patients received chemotherapy with S-1 plus low-dose cisplatin and radiation. Irradiation was targeted at the primary tumor and surrounding lesions, including the lymph nodes. Grade 4 toxicity was observed in only 1 patient, and no treatment-related deaths were noted. After treatment, 3 patients achieved a partial response and 4 achieved stable disease. Of the 9 patients, 8 were able to tolerate solid food orally and were discharged. The outcomes of these cases suggest that OA is a useful adjunctive therapy that enables advanced gastric cancer patients with MGO to receive S-1-containing chemotherapy.

KW - Chemoradiotherapy

KW - Gastric cancer

KW - Malignant gastrointestinal obstruction

KW - Octreotide acetate

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=77954925186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954925186&partnerID=8YFLogxK

U2 - 10.3892/ol_00000118

DO - 10.3892/ol_00000118

M3 - Article

AN - SCOPUS:77954925186

VL - 1

SP - 673

EP - 677

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -